Cingulate Inc
CING3.540USD
+0.020+0.57%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
17.31MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cingulate Inc Unternehmen
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Unternehmensinformationen
BörsenkürzelCING
Name des UnternehmensCingulate Inc
IPO-datumOct 07, 2021
CEOMs. Jennifer L. Callahan
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeOct 07
Addresse1901 W. 47Th Place
StadtKANSAS CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl66205
Telefon19139422300
Websitehttps://www.cingulate.com/
BörsenkürzelCING
IPO-datumOct 07, 2021
CEOMs. Jennifer L. Callahan
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Andere
94.31%
Aktionäre
Aktionäre
Anteil
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Andere
94.31%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
4.09%
Corporation
1.81%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.38%
Venture Capital
0.20%
Hedge Fund
0.03%
Andere
92.93%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
44
305.06K
5.93%
+1.66K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Datum
Art
Verhältnis
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
